Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor

AIDS

Volumn 26, Issue 14, 2012, Pages 1801-1805

  Bittar, Randa ^a,b,c   Giral, Philippe ^b,c,d   Aslangul, Elisabeth ^e,f   Assoumou, Lambert ^b,c   Valantin, Marc A ^b,c,d   Kalmykova, Olga ^b,c   Federspiel, Marie C ^a   Cherfils, Corinne ^a   Costagliola, Dominique ^b,c,d   Bonnefont Rousselot, Dominique ^a,f  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HÔTEL DIEU   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

atherogenic phenotype; HIV 1; low density lipoprotein subfractions; pravastatin; protease inhibitor; rosuvastatin

Indexed keywords

LOW DENSITY LIPOPROTEIN; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; RITONAVIR BOOSTED PROTEASE INHIBITOR; ROSUVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; GEL ELECTROPHORESIS; GRADIENT GEL ELECTROPHORESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; FLUOROBENZENES; FRANCE; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MIDDLE AGED; PRAVASTATIN; PYRIMIDINES; RITONAVIR; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84866328936     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328357063c     Document Type: Article

References (20)

1. Aslangul E, Assoumou KL, Bittar R, Valantin MA, Kalmykova O, Peytavin G, et al. Rosuvastatin versus pravastatin in dyslipi-demic HIV-infected patients receiving protease inhibitors: the ANRS 126 randomized trial. AIDS 2010; 24:77-83.
2. Badiou S, Merle De Boever C, Dupuy AM, Baillet V, Cristol JP, et al. Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of ather-ogenicity? Atherosclerosis 2003; 168:107-113. (Pubitemid 36555817)
3. Tien PC, Schneider MF, Cox C, Cohen M, Karim R, Lazar J, et al. HIV, HAART, and lipoprotein particle concentrations in the Women's Interagency HIV Study. AIDS 2010; 24:2809-2817.
4. Bittar R, Giral P, Aslangul E, Assoumou L, Valantin MA, Kalmykova O, et al. Determinants of low-density lipoprotein particle diameter during antiretroviral therapy including protease inhibitors in HIV-1-infected patients. Antivir Ther 2012. [Epub ahead of print]
5. Grunfeld C. Understanding the complications of antiretroviral drugs. Clin Infect Dis 2008; 47:575-576.
6. Rizzo M, Berneis K. The clinical relevance of low-density-lipoproteins size modulation by statins. Cardiovasc Drugs Ther 2006; 20:205-217. (Pubitemid 44121036)
7. Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterization of human-high-density lipoproteins by gradient gel electrophor-esis. Biochim Biophys Acta 1981; 665:408-419. (Pubitemid 11011381)
8. Vekic J, Zeljkovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Bogavac-Stanojevic N, Memon L, et al. Small, dense LDL and apolipoprotein B: relationship with serum lipids and LDL size. Atherosclerosis 2009; 207:496-501.
9. Krauss RM, Blanche PJ. Detection and quantification of LDL subfractions. Curr Opin Lipidol 1992; 3:377-383.
10. Friedlander Y, Kidron M, Casalke M, Lamb T, Mc Connell M, Bar-On H. Low density lipoprotein particle size and risk factors of insulin resistance syndrome. Atherosclerosis 2000; 148:141-149.
11. Berneis K, Jeanneret C, Muser J, Felix B, Miserez AR. Low density lipoprotein size and subclasses are markers of clinically apparent and nonapparent atherosclerosis in type 2 diabetes. Metabolism 2005; 54:227-234. (Pubitemid 40174852)
12. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM 2006; 99:1-14. (Pubitemid 43124966)
13. Rubba P, Marotta G, Gentile M. Efficacy and safety of rosu-vastatin in the management of dyslipidemia. Vasc Health Risk Manag 2009; 5:343-352.
14. Bahadir MA, Oguz A, Uzunlulu M, Bahadir O. Effects of different statin treatment on small dense low-density lipopro-tein in patients with metabolic syndrome. J Atheroscler Thromb 2009; 16:684-690.
15. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronaries (PLAC-I). Am J Cardiol 2002; 90:89-94. (Pubitemid 34775113)
16. Otvos JD, Shalaurova I, Freedman DS, Rosenson RS. Effects of pravastatin treatment on lipoprotein subclass profiles and particle sizeinthe PLAC-I trial. Atherosclerosis2002; 160:41-48. (Pubitemid 34082715)
17. Cheung MC, Austin MA, Moulin P, Wolf AC, Cryer D, Knopp RH. Effects of pravastatin on apolipolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholester-olemia. Atherosclerosis 1993; 102:107-119. (Pubitemid 23269736)
18. Sirtori CR, Calabresi L, Pisciotta L, Cattin L, Pauciullo P, Mon-tagnani M, et al. Effects of statins on LDL particle size in patients with familial combined hyperlipemia: a comparison between atorvastatin and pravastatin. Nutr Metab Cardiovasc Dis 2005; 15:47-55. (Pubitemid 40546034)
19. Van der Graaf A, Rodenburg J, Vissers MN, Hutten BA, Wiegman A, Trip MD, et al. Atherogenic lipoprotein particle size and concentrations and the effect of pravastatin in children with familial hypercholesterolemia. J Pediatr 2008; 152:873-878.
20. Casalke MJ, Stewart G, Day PD, Daly E, McTaggart F, Chapman MJ, et al. Phenotype-dependent and independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyper-lipidaemia. Atherosclerosis 2003; 171:245-253. (Pubitemid 37486076)